TrialAnnals of the rheumatic diseases2014

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.

Bruce W Kirkham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.